Heron Therapeutics, Inc, a biotechnology company, engages in developing treatments to address unmet medical needs. The company's product candidates utilize its proprietary Biochronomer drug delivery technology, which delivers therapeutic levels of a range of short-acting pharmacological agents over a period from days to weeks with a single administration.
Read More…
Industry, Sector and Symbol
Industry Pharmaceutical preparations
Sub-IndustryN/A
SectorMedical
Phone858-251-4400
Debt
Price-To-Earnings
Sales & Book Value
Annual Sales$77.47 million
Profitability
Miscellaneous
Employees198
Next Earnings Date11/6/2019 (Estimated)
OptionableOptionable
Heron Therapeutics (NASDAQ:HRTX) Frequently Asked Questions
What is Heron Therapeutics' stock symbol?
Heron Therapeutics trades on the NASDAQ under the ticker symbol "HRTX."
How were Heron Therapeutics' earnings last quarter?
Heron Therapeutics Inc (NASDAQ:HRTX) announced its quarterly earnings data on Monday, August, 5th. The biotechnology company reported ($0.63) EPS for the quarter, beating the Thomson Reuters' consensus estimate of ($0.65) by $0.02. The biotechnology company had revenue of $36.66 million for the quarter, compared to the consensus estimate of $31.04 million. Heron Therapeutics had a negative return on equity of 56.89% and a negative net margin of 172.07%. View Heron Therapeutics' Earnings History.
When is Heron Therapeutics' next earnings date?
What price target have analysts set for HRTX?
6 Wall Street analysts have issued 1 year price targets for Heron Therapeutics' shares. Their forecasts range from $38.00 to $75.00. On average, they expect Heron Therapeutics' stock price to reach $56.40 in the next year. This suggests a possible upside of 190.6% from the stock's current price. View Analyst Price Targets for Heron Therapeutics.
What is the consensus analysts' recommendation for Heron Therapeutics?
6 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Heron Therapeutics in the last year. There are currently 1 hold rating and 5 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for Heron Therapeutics.
What are Wall Street analysts saying about Heron Therapeutics stock?
Here are some recent quotes from research analysts about Heron Therapeutics stock:
- 1. Evercore ISI analysts commented, "We remain highly constructive on the name as ‘011’s differentiated product profile and today’s opioid awareness environment should help propel adoption of the product in a wide range of surgical procedures. We’ve updated the model following earnings; PT remains $75 (OP). HRTX is confident that the answers to the FDA’s CRL are readily addressed. We will likely see a press release after the NDA is refiled, and the company plans to request a Type A meeting. The key dislocation: the company’s ‘011 timelines have reset, but the commercial opportunity remains unchanged. With the stock trading at these levels, we continue to see substantial upside if the company can execute its launch strategy." (8/13/2019)
- 2. Stifel Nicolaus analysts commented, "We are reiterating our Buy rating and $38 target price on HRTX shares after the company reported a nice sales beat driven by Cinvanti and provided a incremental update indicating it plans to meet with the FDA shortly" to discuss the responses to the CRL it received in May for HTX-011. We remain positive on HTX-011’s approvability as a local, non-opioid analgesic and given the low visibility into the company’s CRL resolution process, we think today’s update could suggest we are nearing a more material one on this front. We continue to view this as the company’s key upcoming catalyst." (8/5/2019)
- 3. Northland Securities analysts commented, "We believe these requirements are addressable, and anticipate resubmission prior to YE19, w/ approval in late-1H2020 or earlier. Heron Therapeutics reported 2Q results, with topline results beating expectations and EPS aligned with consensus. Product sales totaled $36.7MM, vs. our forecast of $32.3MM and the consensus of $31.8MM, respectively. Topline results reflected continued strength of CINVANTI, which posted sales of $33.2MM vs. our forecast of $28.5MM. CINVANTI sales advanced significantly sequentially from $28.0MM. SUSTOL sales were flat at $3.5MM, reflecting continued pressure from arbitrage relating to generic entry of palonestron. Importantly, Heron reiterated full-year product sales guidance of $115MM-to-$120MM. Operating loss and EPS were aligned with our expectations at ($51.8MM) and ($0.63), respectively." (8/5/2019)
- 4. Cowen Inc analysts commented, ": Post 1Q19, we are reiterating our Overweight rating and $18 PT on CHMA. We believe the stock continues to trade at a significant discount to its potential intrinsic value. We believe the risk-reward going into Phase 3 data for Mycapssa (oral octreotide) for the treatment of acromegaly, to be released in 3Q19, remains positive. As the company advances Mycapssa toward approval, we expect data readouts, approvals, and upward earnings revisions to drive CHMA’s stock higher." (5/9/2019)
- 5. According to Zacks Investment Research, "Heron Therapeutics Inc. is a specialty pharmaceutical company. The company is developing products using its proprietary Biochronomer (TM) polymer-based drug delivery platform. Its product portfolio includes APF530, is being developed for the prevention of acute chemotherapy-induced nausea and vomiting. Heron Therapeutics Inc., formerly known as A.P. Pharma, Inc., is based in REDWOOD CITY CA. " (5/9/2019)
Has Heron Therapeutics been receiving favorable news coverage?
Media stories about HRTX stock have been trending negative recently, according to InfoTrie Sentiment Analysis. The research group identifies negative and positive press coverage by reviewing more than six thousand news and blog sources in real time. The firm ranks coverage of public companies on a scale of negative five to five, with scores nearest to five being the most favorable. Heron Therapeutics earned a media sentiment score of -2.9 on InfoTrie's scale. They also assigned news stories about the biotechnology company a news buzz of 10.0 out of 10, meaning that recent press coverage is extremely likely to have an effect on the company's share price in the near term. View News Stories for Heron Therapeutics.
Who are some of Heron Therapeutics' key competitors?
Some companies that are related to Heron Therapeutics include Dr.Reddy's Laboratories (RDY), Beigene (BGNE), Sarepta Therapeutics (SRPT), ACADIA Pharmaceuticals (ACAD), Amarin (AMRN), Horizon Therapeutics (HZNP), Ascendis Pharma A/S (ASND), GW Pharmaceuticals PLC- (GWPH), Blueprint Medicines (BPMC), The Medicines (MDCO), United Therapeutics (UTHR), Mirati Therapeutics (MRTX), FibroGen (FGEN), Nektar Therapeutics (NKTR) and Allakos (ALLK).
What other stocks do shareholders of Heron Therapeutics own?
Who are Heron Therapeutics' key executives?
Heron Therapeutics' management team includes the folowing people:
- Dr. Barry D. Quart, Pres, CEO & Director (Age 62)
- Mr. Robert E. Hoffman C.P.A., CPA, CFO & Sr. VP of Fin. (Age 53)
- Ms. Kimberly J. Manhard, Exec. VP of Drug Devel. (Age 59)
- Mr. David L. Szekeres, Sr. VP of Bus. Devel., Gen. Counsel & Corp. Sec. (Age 45)
- Mr. Sean T. Ristine, VP of HR (Age 49)
Who are Heron Therapeutics' major shareholders?
Heron Therapeutics' stock is owned by many different of retail and institutional investors. Top institutional shareholders include Vanguard Group Inc. (8.45%), Janus Henderson Group PLC (6.45%), Janus Henderson Group PLC (6.45%), BlackRock Inc. (6.14%), Eagle Asset Management Inc. (1.82%) and JPMorgan Chase & Co. (1.80%). Company insiders that own Heron Therapeutics stock include Barry D Quart, John Poyhonen, Kevin C Tang, Kimberly Manhard, Robert Hoffman, Robert Rosen and Waage Christian. View Institutional Ownership Trends for Heron Therapeutics.
Which institutional investors are selling Heron Therapeutics stock?
HRTX stock was sold by a variety of institutional investors in the last quarter, including Allianz Asset Management GmbH, Rock Springs Capital Management LP, Wells Fargo & Company MN, UBS Oconnor LLC, Eagle Asset Management Inc., University of Notre Dame DU Lac, D. E. Shaw & Co. Inc. and Janus Henderson Group PLC. View Insider Buying and Selling for Heron Therapeutics.
Which institutional investors are buying Heron Therapeutics stock?
HRTX stock was acquired by a variety of institutional investors in the last quarter, including JPMorgan Chase & Co., C WorldWide Group Holding A S, Heartland Advisors Inc., Nuveen Asset Management LLC, Sofinnova Investments Inc., Vanguard Group Inc., Fosun International Ltd and Renaissance Technologies LLC. Company insiders that have bought Heron Therapeutics stock in the last two years include John Poyhonen, Kevin C Tang and Waage Christian. View Insider Buying and Selling for Heron Therapeutics.
How do I buy shares of Heron Therapeutics?
Shares of HRTX can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity and Charles Schwab.
What is Heron Therapeutics' stock price today?
One share of HRTX stock can currently be purchased for approximately $19.41.
How big of a company is Heron Therapeutics?
Heron Therapeutics has a market capitalization of $1.55 billion and generates $77.47 million in revenue each year. The biotechnology company earns $-178,840,000.00 in net income (profit) each year or ($2.44) on an earnings per share basis. Heron Therapeutics employs 198 workers across the globe.View Additional Information About Heron Therapeutics.
What is Heron Therapeutics' official website?
How can I contact Heron Therapeutics?
Heron Therapeutics' mailing address is 4242 CAMPUS POINT COURT SUITE 200, SAN DIEGO CA, 92121. The biotechnology company can be reached via phone at 858-251-4400 or via email at [email protected]
MarketBeat Community Rating for Heron Therapeutics (NASDAQ HRTX)
MarketBeat's community ratings are surveys of what our community members think about Heron Therapeutics and other stocks. Vote "Outperform" if you believe HRTX will outperform the S&P 500 over the long term. Vote "Underperform" if you believe HRTX will underperform the S&P 500 over the long term. You may vote once every thirty days.
